Abstract:Aims: Agomelatine is an antidepressant for major depressive disorders. It undergoes extensive first-pass hepatic metabolism and displays irregular absorption profiles and large interindividual variability (IIV) and interoccasion variability of pharmacokinetics. The objective of this study was to characterize the complex pharmacokinetics of agomelatine and its metabolites in healthy subjects. Methods: Plasma concentration-time data of agomelatine and its metabolites were collected from a 4-period, cross-over bioequivalence study, in which 44 healthy subjects received 25 mg agomelatine tablets orally. Nonlinear mixed effects modelling was used to characterize the pharmacokinetics and variability of agomelatine and its metabolites. Deterministic simulations were carried out to investigate the influence of pathological changes due to liver disease on agomelatine pharmacokinetics. Results: A semiphysiological pharmacokinetic model with parallel first-order absorption and a well-stirred liver compartment adequately described the data. The estimated IIV and interoccasion variability of the intrinsic clearance of agomelatine were 130.8% and 28.5%, respectively. The IIV of the intrinsic clearance turned out to be the main cause of the variability of area under the curve-based agomelatine exposure. Simulations demonstrated that a reduction in intrinsic clearance or liver blood flow, and an increase in free drug fraction had a rather modest influence on agomelatine exposures (range: -50 to 200%). Portosystemic shunting, however, substantially elevated agomelatine exposure by 12.6-109.1-fold. Conclusions: A semiphysiological pharmacokinetic model incorporating first-pass hepatic extraction was developed for agomelatine and its main metabolites. The portosystemic shunting associated with liver disease might lead to significant alterations of agomelatine pharmacokinetics, and lead to substantially increased exposure.

Quantification and structural elucidation of potential impurities in agomelatine active pharmaceutical ingredient.

LC-MS/MS Method for the Determination of Agomelatine in Human Plasma and Its Application to a Pharmacokinetic Study.

Introduction of Synthesis Method of Agomelatine

Pharmacological actions and clinical efficacy of agomelatine

A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers

Agomelatine:a new antidepressant drug

Oxymatrine ameliorates agomelatine-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation

Influence of Temperature, Solvents, and Excipients on Crystal Transformation of Agomelatine

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

Isolation and structure characterization of related impurities in 10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate (XQ-1H) bulk drug and quantitation by a validated RP-LC.

Focus on agomelatine

Study on the Polymorphism of Agomelatine

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

Scaffold Hopping Toward Agomelatine: Novel 3, 4-Dihydroisoquinoline Compounds as Potential Antidepressant Agents

Systematic Review of the Efficacy of Agomelatine in the Treatment of Depression in Acute Phase

Inter- And Intra-Individual Variability In The Pharmacokinetics Of Agomelatine Tablets In Chinese Healthy Male Subjects

Isolation and Structural Elucidation of an Unknown Impurity in Prasugrel by Semi-Preparative Liquid Chromatography.

Physicochemical Characterization and Pharmacokinetics of Agomelatine-Loaded PLGA Microspheres for Intramuscular Injection

Efficacy and safety of agomelatine and SSRIs or SNRIs treating depression: a Meta-analysis

Evaluation Of The Highly Variable Agomelatine Pharmacokinetics In Chinese Healthy Subjects To Support Bioequivalence Study

Novel cocrystals of agomelatine, synthesis method thereof and pharmaceutical compositions containing same